349 related articles for article (PubMed ID: 23254770)
1. Population pharmacokinetics of losmapimod in healthy subjects and patients with rheumatoid arthritis and chronic obstructive pulmonary diseases.
Yang S; Lukey P; Beerahee M; Hoke F
Clin Pharmacokinet; 2013 Mar; 52(3):187-98. PubMed ID: 23254770
[TBL] [Abstract][Full Text] [Related]
2. Safety, tolerability, pharmacokinetics, and pharmacodynamics of losmapimod in healthy Japanese volunteers.
Ino H; Takahashi N; Terao T; Igarashi H; Sarai N
Clin Pharmacol Drug Dev; 2015 Jul; 4(4):262-9. PubMed ID: 27136906
[TBL] [Abstract][Full Text] [Related]
3. Safety, tolerability, pharmacokinetics and pharmacodynamics of losmapimod following a single intravenous or oral dose in healthy volunteers.
Barbour AM; Sarov-Blat L; Cai G; Fossler MJ; Sprecher DL; Graggaber J; McGeoch AT; Maison J; Cheriyan J
Br J Clin Pharmacol; 2013 Jul; 76(1):99-106. PubMed ID: 23215699
[TBL] [Abstract][Full Text] [Related]
4. Losmapimod concentration-QT relationship in healthy volunteers: meta-analysis of data from six clinical trials.
Yang S; Beerahee M
Eur J Clin Pharmacol; 2013 Jun; 69(6):1261-7. PubMed ID: 23325437
[TBL] [Abstract][Full Text] [Related]
5. The p38 mitogen activated protein kinase inhibitor losmapimod in chronic obstructive pulmonary disease patients with systemic inflammation, stratified by fibrinogen: A randomised double-blind placebo-controlled trial.
Fisk M; Cheriyan J; Mohan D; Forman J; Mäki-Petäjä KM; McEniery CM; Fuld J; Rudd JHF; Hopkinson NS; Lomas DA; Cockcroft JR; Tal-Singer R; Polkey MI; Wilkinson IB
PLoS One; 2018; 13(3):e0194197. PubMed ID: 29566026
[TBL] [Abstract][Full Text] [Related]
6. Biological effects of p38 MAPK inhibitor losmapimod does not translate to clinical benefits in COPD.
Pascoe S; Costa M; Marks-Konczalik J; McKie E; Yang S; Scherbovsky PS
Respir Med; 2017 Sep; 130():20-26. PubMed ID: 29206629
[TBL] [Abstract][Full Text] [Related]
7. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
Zhou H; Mayer PR; Wajdula J; Fatenejad S
J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model.
Lahu G; Hünnemeyer A; Diletti E; Elmlinger M; Ruth P; Zech K; McCracken N; Facius A
Clin Pharmacokinet; 2010 Sep; 49(9):589-606. PubMed ID: 20690782
[TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I-III Clinical Trials.
Klünder B; Mittapalli RK; Mohamed MF; Friedel A; Noertersheuser P; Othman AA
Clin Pharmacokinet; 2019 Aug; 58(8):1045-1058. PubMed ID: 30945116
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial.
Watz H; Barnacle H; Hartley BF; Chan R
Lancet Respir Med; 2014 Jan; 2(1):63-72. PubMed ID: 24461903
[TBL] [Abstract][Full Text] [Related]
11. Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial.
Newby LK; Marber MS; Melloni C; Sarov-Blat L; Aberle LH; Aylward PE; Cai G; de Winter RJ; Hamm CW; Heitner JF; Kim R; Lerman A; Patel MR; Tanguay JF; Lepore JJ; Al-Khalidi HR; Sprecher DL; Granger CB;
Lancet; 2014 Sep; 384(9949):1187-95. PubMed ID: 24930728
[TBL] [Abstract][Full Text] [Related]
12. A post-hoc subgroup analysis of data from a six month clinical trial comparing the efficacy and safety of losmapimod in moderate-severe COPD patients with ≤2% and >2% blood eosinophils.
Marks-Konczalik J; Costa M; Robertson J; McKie E; Yang S; Pascoe S
Respir Med; 2015 Jul; 109(7):860-9. PubMed ID: 26033641
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, safety, and tolerability of GLPG0259, a mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5) inhibitor, given as single and multiple doses to healthy male subjects.
Namour F; Vanhoutte FP; Beetens J; Blockhuys S; De Weer M; Wigerinck P
Drugs R D; 2012 Sep; 12(3):141-63. PubMed ID: 22950522
[TBL] [Abstract][Full Text] [Related]
14. An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease.
Lomas DA; Lipson DA; Miller BE; Willits L; Keene O; Barnacle H; Barnes NC; Tal-Singer R;
J Clin Pharmacol; 2012 Mar; 52(3):416-24. PubMed ID: 22090363
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of tapentadol immediate release (IR) in healthy subjects and patients with moderate or severe pain.
Xu XS; Smit JW; Lin R; Stuyckens K; Terlinden R; Nandy P
Clin Pharmacokinet; 2010 Oct; 49(10):671-82. PubMed ID: 20818833
[TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetic Model of Cabozantinib in Patients with Medullary Thyroid Carcinoma and Its Application to an Exposure-Response Analysis.
Miles D; Jumbe NL; Lacy S; Nguyen L
Clin Pharmacokinet; 2016 Jan; 55(1):93-105. PubMed ID: 26149244
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetics of Total and Free Erdafitinib in Adult Healthy Volunteers and Cancer Patients: Analysis of Phase 1 and Phase 2 Studies.
Dosne AG; Valade E; Stuyckens K; Li LY; Ouellet D; Perez-Ruixo JJ
J Clin Pharmacol; 2020 Apr; 60(4):515-527. PubMed ID: 31742712
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
[TBL] [Abstract][Full Text] [Related]
19. Development of population pharmacokinetics model of icotinib with non-linear absorption characters in healthy Chinese volunteers to assess the CYP2C19 polymorphism and food-intake effect.
Hu P; Chen J; Liu D; Zheng X; Zhao Q; Jiang J
Eur J Clin Pharmacol; 2015 Jul; 71(7):843-50. PubMed ID: 25995169
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetic analysis of axitinib in healthy volunteers.
Garrett M; Poland B; Brennan M; Hee B; Pithavala YK; Amantea MA
Br J Clin Pharmacol; 2014 Mar; 77(3):480-92. PubMed ID: 23834452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
